Abstract
The purpose of this study was to produce of microparticles for Dry Powder Inhalation, produced by environmentally driven In-situ Microcronization technique at different processing parameters, for inhalation therapy. Typically particle size reduction process employs jet-milling technology which can be destructive to the solid-state properties of the particles. Salbutamol Sulphate, as one of the β2-adrenoceptor stimulant commonly used in the treatment of bronchial asthmaby pulmonary delivery.The objective of the current work was to developed microcrystals by using In-situ Microcronization technique with different processing parameters. A response surface type central composite design were employed using Design-Expert 5.0 software (Stat Ease, QD Consulting, Penzance, UK) with the factors investigated werestirrer speeds investigated were 500(-1), 1000(0) and 1500 (1) rpm, addition rate of non-solvent i.e ethanol was studied at 50(-1), 100(0) and 150(1) g /min and stabilizer conc. were 0.5(-1), 1(0) and 1.5 %( 1). In the bottom up technique of micro sizing we use in-situmicronization technique which carried out using the solvent change method in presence of HPMC as stabilizing agent. The suspension wasspray dried thereafter.Optimize the process variables for less mean particle size and high Fine Particle Fraction (FPF). Spray dried crystals were subjected to XRD, FTIR, DSC and SEM analysis for stability. The PSD and FPF also depended on the balance of meso and micromixing determined by the crystallization conditions. Optimized formulation was identified and characterized to determine their suitability for pulmonary delivery by using MSLI. Optimized formulation showed the highest FPF loaded and FPF emitted of 78 (1%) and 84 ( 3%) respectively, depositing mainly on stages 3 and 4, with much lower amounts collected on the higher stages of the MSLI.
References
Sakagami, M., 2006. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 58, 1030–1060.
Newman, S., Wilding, I.R., Hirst, P.H., 2010. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int. J. Pharm. 208, 49–60.
Misra, A., Hickey, A.J., Rossi, C., Borchard, G., Terada, H., Makino, K., Fourie, P.B., Colomboh, P., 2011. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis 91, 71–81.
Sherwood, L., 2010. Human Physiology: From Cells to Systems, 7th ed. Brooks/Cole CengageLearning, United States of America.
Sung, J.C., Pulliam, B.L., Edwards, D.A., 2007. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 25, 563–570.
Bhavna, Ahmed, F.J., Mittal, G., Jain, G.K., Malhotra, G., Khar, R.K., Bhatnagar, A., 2009.
Nano-salbutamol dry powder inhalation: a new approach for treating bronchoconstrictive conditions. Eur. J. Pharmaceut. Biopharmaceut. 71, 282–291.
Cook, R.O., Pannu, R.K., Kellaway, I.W., 2005. Novel sustained release microspheres for pulmonary drug delivery. J. Control. Release 104, 79–90.
Learoyd, T.P., Burrows, J.L., French, E., Seville, P.C., 2008. Modified release of beclomethasonedipropionate from chitosan-based spray-dried respirable powders. Powder Technol. 187, 231–238.
Learoyd, T.P., Burrows, J.L., French, E., Seville, P.C., 2009. Sustained delivery by leucine-modified United States of America chitosan spray-dried respirable powders. Int. J. Pharmaceut. 372, 97–104.
Kwon, M.J., Bae, J.H., Kim, J.J., Na, K., Lee, E.S., 2007. Long acting porous microparticle for pulmonary protein delivery. Int. J. Pharmaceut. 333, 5–9.
National Heart, Lung and Blood Institute, National Institute of Health—Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention. NHBLI/WHO workshop report, 1995, NIH publication number 95-3659.
Zanen, P., Lammers, J-W.J., 1995. Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence. J. Clin. Pharmacol. 48, 179_/184.
Pasquali, R. Bettini, F. Giordano, Solid-state and particle engineering with supercritical fluids in pharmaceutics, European J. Pharmaceutical Sciences 27 (2006) 299–310.
V. Naini, P.R. Byron, E.M. Phillips, Physicochemical stability of crystalline sugar and their spray-dried forms: dependence upon relative humidity and suitability for use in powder inhalers, Drug Development and Industrial Pharmacy 24 (1998) 895–909.
Malcolmson, R.J., Embleton, J.K., 1998. Dry powder formulations for pulmonary delivery. Pharm. Sci. Technol. Today 1, 394–398.
Müller, R.H., Peters, K., Becker, R., Kruss, B., 1996. Nanosuspensions for the i.v. administration of poorly soluble drugs—stability during sterilization and long-term storage. Proc. Int. Symp. Control Rel. Bioact. Mater. 22, 574–575.
Roberts, R.J., Rowe, R.C., York, P., 1994. The relationship between indentation hardness of organic solids and their molecular structure. J. Mater. Sci. 29, 2289–2296.
.Parrott, E.L., 1990. Comminution. In: Swarbrick, J., Boylan, J.C. (Eds.), Encyclopedia of Pharmaceutical Technology, vol. 3. Marcel Decker, New York, pp. 101–121.
Ogura, K., Sobue, H., 1970. Changes in morphology with milling of the commercial microcrystalline cellulose. J. Appl. Polymer Sci. 14, 1390–1393.
Ward G.H., Schultz, R.K., 1995. Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability. Pharm. Res. 12, 773–779.
Schott, H., 1985. Colloidal dispersions. In: Remington’s Pharmaceutical Sciences. The Philadelphia College of Pharmacy and Science, Philadelphia, pp. 286–289.
Buckton, G., 1997. Characterization of small changes in the physical properties of powders of significance for dry powder inhaler formulations. Adv. Drug Del. Rev. 26, 17–27.
Williams, R.O., Brown, J., Liu, J., 1999. Influence of micronization method on the performance of a suspension triamcinolone acetonide pressurized metered-dose inhaler formulation. Pharm. Dev. Technol. 4, 167–179.
Feeley, J.C., York, P., Sumby, B.S., Dicks, H., 1998. Determination of surface properties and flow characteristics of salbutamol sulphate, before and after micronization. Int. J. Pharm. 172, 89–96.
Mackin, L., Sartnurak, S., Thomas, I., Moore, S., 2002. The impact of low levels of amorphous material (<5%) on the blending characteristics of a direct compression formulation. Int. J. Pharm. 231, 213–226.
Taylor, K.M.G., Pancholi, K., Wong, D.Y.T., 1999. In- vitro evaluation of dry powder inhaler formulations of micronized and milled nedocromil sodium. Pharm. Pharmacol. Commun. 5, 255–257.
G.M.J. Schmidt, Topochemistry. Part III. The crystal chemistry of some trans-cinnamic acids, J. Chem. Soc. (1964) 2014.
HartwigSteckel, Norbert Rasenack, Bernd W. Mu¨ller, In-situ-micronization of disodium cromoglycate for pulmonary delivery, European Journal of Pharmaceutics and Biopharmaceutics 55 (2003) 173–180
HartwigSteckel a, Norbert Rasenack a, Peter Villax b, Bernd W. Müller a, In vitro characterization of jet-milled and in-situ-micronized fluticasone-17- propionate, International Journal of Pharmaceutics 258 (2003) 65–75
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array